Chimeric Therapeutics (ASX:CHM) ROE % Adjusted to Book Value : 27.21% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics ROE % Adjusted to Book Value?

Chimeric Therapeutics's ROE % for the quarter that ended in Dec. 2023 was 50.07%. Chimeric Therapeutics's PB Ratio for the quarter that ended in Dec. 2023 was 1.84. Chimeric Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 27.21%.

Chimeric Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Chimeric Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics ROE % Adjusted to Book Value Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

ROE % Adjusted to Book Value

-15.70

-40.88

-47.13

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial			-18.16	-37.59	-52.22	-73.77	27.21

Competitive Comparison of Chimeric Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Chimeric Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's ROE % Adjusted to Book Value falls into.

Chimeric Therapeutics ROE % Adjusted to Book Value Calculation

Chimeric Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-162.59%	/	3.45
	=	-47.13%

Chimeric Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	50.07%	/	1.84
	=	27.21%

Chimeric Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines